

- A4
12. (Amended) Compound of formula (IV) in which A is defined as in [any one of claims 1 to 8] claim 1.
13. (Amended) Compound according to [one of claims 11 or 12] claim 11, characterised in that the coupling between the linear peptide (A) and group (Z) or groups (Z) and (Y) is made by one or more covalent, hydrophobic or ionic bonds.
14. (Amended) Compound according to [any one of claims 11 to 13] claim 11, characterised in that at least one of the active substances (Z) is attached by a covalent bond either to the N-terminal or C-terminal ends or to the primary amino groups, carried by the side chains of the lysines, of linear peptide (A).
15. (Amended) Compound according to any [one of claims 11 to 14] claim 11, characterised in that at least one signal agent (Y), if present, is attached by a covalent bond to the N-terminal end of linear peptide (A).
16. (Amended) Pharmaceutical composition, characterised in that as active ingredient it comprises at least one compound of formula (TV) according to [any one of claims 11 to 15] claim 11.
17. (Amended) Diagnostic agent made up of at least one compound of formula (TV) according to any one of [claims 11 to 15] claim 11.

REMARKS


Applicant has amended claims 3, 5-8, 10, and 12-17 to remove dependency from multiple dependent claims. 37 C.F.R. § 1.75(c). No new matter is added.

INVENTORS: Calas *et al.*
UNITED STATES
NATIONAL PHASE OF PCT/FR98/01757
PCT INTERNATIONAL
APPLICATION NO:

CONCLUSION

Applicant requests that the Examiner enter these amendments and issue these claims. If the Examiner has any further issues, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
John Prince, Reg. No. 43,019
Attorneys for Applicants

c/o MINTZ LEVIN COHN FERRIS GLOVSKY AND
POPEO PC
One Financial Center
Boston, Massachusetts 02111
Telephone: (617) 542-6000
Telefax: (617) 542-2241

TRADOCS:1294895.1(RR5B01!.DOC)
02/11/00 3:51 PM